Metraipolis › archive › dc_7db452f1b403

Strong Signals of Adverse Events in Tyrosine Kinase Inhibitor Therapy for Liver Cancer Treatment — Europe PMC PMID:41822321

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41822321
DOI
10.14740/wjon2685
License (as archived)
solo-consultazione
Archived
2026-11-07T02:09:17.968Z
SHA-256 of the archived text
f7c6c586bb3883831cf38abc3faaaf779ec7dfeb643063dddc9e6333889ad269
Stable URL of this page
https://metraipolis.com/documento/dc_7db452f1b403

How to cite

Strong Signals of Adverse Events in Tyrosine Kinase Inhibitor Therapy for Liver Cancer Treatment — Europe PMC PMID:41822321 — Europe PMC (en), https://europepmc.org/article/MED/41822321 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7db452f1b403 (Metraipolis archive dc_7db452f1b403, sha256 f7c6c586bb3883831cf38abc3faaaf779ec7dfeb643063dddc9e6333889ad269)
BibTeX
@misc{dc7db452f1b403,
  title = {Strong Signals of Adverse Events in Tyrosine Kinase Inhibitor Therapy for Liver Cancer Treatment — Europe PMC PMID:41822321},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41822321},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7db452f1b403; sha256 f7c6c586bb3883831cf38abc3faaaf779ec7dfeb643063dddc9e6333889ad269},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41822321. Agents can read the archived copy with the MCP tool read_document.